Global expansion AtomVie is rapidly expanding its radiopharmaceutical manufacturing footprint with a new Hamilton facility and a recent expansion into Independence, Kansas, signaling growing capacity and readiness to service North American clinical and commercial supply chains. Sales teams should explore multi-site CDMO partnerships, both for regional coverage and for risk mitigation across U.S. and Canada.

Strategic partnerships The company has established notable collaborations and agreements, including a long-term supply deal with TerraPower Isotopes for Ac-225 and a collaboration with Radiopharm Theranostics Limited. This demonstrates a readiness to engage in high-value, hard-to-source isotopes and joint development programs, presenting upsell opportunities for expanded radiopharmaceutical development and supply management.

Investor and funding signals AtomVie is actively attracting investment and financing, with substantial capital raises and government-backed funding (e.g., Invest Ontario) alongside a large facility investment. This suggests a favorable funding environment for additional GMP capabilities, scale-up projects, and new radiopharmaceutical programs requiring partner financing or co-development options.

Leadership and capability Recent senior hires and a strong leadership team (including a Chief Business Officer appointment) indicate a strategic push toward business development, regulatory, quality, and commercial readiness. This is an opportunity to position value propositions around end-to-end CDMO services, regulatory support, and accelerated market access for novel radiopharmaceuticals.

Market positioning As a global leading radiopharmaceutical CDMO with Phase 1 through commercial manufacturing capabilities, AtomVie targets high-growth segments in clinical and commercial radiopharmacy. Prospect conversations can emphasize risk-managed scale-up, reliable supply chains, and access to specialty isotopes and advanced therapeutics to differentiate from traditional CDMOs.